Evidence map›Paper›PMID 42017060›Full record

ArticleJHLT open2026

Universal screening for hyperammonemia after lung transplantation: A retrospective cohort study of incidence and outcomes.

Katherine D Wick, Jagadish Patil, Jordan Dunitz, JoAnne Billings, Sarah Kiel, Kathleen Mahan, Christine Lambert, Marshall Hertz, Sara Shumway, Houachee Lee and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Katherine D WickDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Jagadish PatilDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Jordan DunitzDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
JoAnne BillingsDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Sarah KielDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Kathleen MahanDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Christine LambertDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Marshall HertzDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Sara ShumwayDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.
Houachee LeeAnalytic Consulting Service, MHealth Fairview, Minneapolis, MN.
Stephen HuddlestonDivision of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.
Anupam KumarDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hyperammonemia after lung transplant (HALT) is a highly morbid condition with variation in approaches to detection and treatment across centers. Traditionally, HALT has been defined as a serum ammonia level greater than 200 μmol/L; however, patients may be at risk of adverse outcomes at lower levels. We studied outcomes associated with a universal screening protocol for elevated serum ammonia. Methods: This was a retrospective study of lung transplant recipients at the University of Minnesota between 2013 and 2024. Screening was implemented in October of 2021. We defined hyperammonemia as serum ammonia of 50 μg/dLμmol/L or greater and HALT as those patients in whom hyperammonemia prompted treatment based on clinician judgment. Our primary outcome was 90-day mortality. We compared the incidence of elevated serum ammonia, HALT, 90-day mortality, hospital and intensive care unit lengths of stay, and HALT-focused treatments before and after protocol implementation. The relationship between HALT and 90-day mortality was tested using a multivariable Cox proportional hazards model. The relationship between pre-selected risk factors and HALT was also tested using multivariable logistic regression. Results: There was a significantly higher number of patients with elevated serum ammonia (13.6% post-protocol vs 4.3% pre-protocol, Conclusion: Universal screening for hyperammonemia was associated with a lower adjusted risk of death. Ammonia levels as low as 50 μmol/L were associated with an increased risk of adverse outcomes. Centers should consider protocolized screening and treatment for HALT, which may improve outcomes of lung transplant.

Indexed as

HyperammonemiaLung transplantMollicute infectionPost-transplant mortalityUniversal screening

Identifiers

PMID42017060
PMCPMC13092655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.